Publications

  • Journal Papers
  • Invention Patent

      PUBLICATION

  1. Moran CJ, Arenberg DA, Huang CCGiordano TJ, Thomas DG, Misek DEChen GIannettoni MDOrringer MBHanash SBeer DG. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res. 2002 Dec;8(12):3803-12. PMID: 12473593 (IF:10.199).
  2. Tarek G. Gharib, Guoan Chen, Hong Wang, Chiang-Ching Huang, Michael S. Prescott, Kerby Shedden, David E. Misek, Dafydd G. Thomas, Thomas J. Giordano, Jeremy M.G. Taylor, Sharon Kardia, John Yee, Mark B. Orringer, Samir Hanash and David G. Beer. Proteomic Analysis of Cytokeratin Isoforms Uncovers Association with Survival in Lung Adenocarcinoma. Neoplasia. 4(5): 440-8, 2002 (IF:4.994).
  3. Guoan Chen, Tarek G. Gharib, Chiang-Ching Huang, Jeremy M. G. Taylor, David E. Misek, Sharon L. R. Kardia, Thomas J. Giordano, Mark D. Iannettoni, Mark B. Orringer, Samir M. Hanash, and David G. Beer. Discordant Protein and mRNA Expression in Lung Adenocarcinomas. Mol Cell Proteomics. 1(4): 304-13, 2002 (IF:5.232).
  4. Guoan Chen, Tarek G. Gharib, Chiang-Ching Huang, Dafydd G. Thomas, Kerby A. Shedden, Jeremy M.G. Taylor, Sharon L.R. Kardia, David E. Misek, Thomas J. Giordano, Mark D. Iannettoni, Mark B. Orringer, Samir M. Hanash, and David G. Beer. Proteomic Analysis of Lung Adenocarcinoma: Identification of a Highly Expressed Set of Proteins in Tumors. Clinical Cancer Research. 8(7): 2298-305, 2002 (IF:10.199).
  5. David G. Beer, Sharon L.R. Kardia, Chiang-Ching Huang, Thomas J. Giordano, Albert M. Levin, David E. Misek, Lin Lin, Guoan Chen, Tarek G. Gharib, Dafydd G. Thomas, Michelle L. Lizyness, RorkKuick, Satoru Hayasaka, Jeremy M.G. Taylor, Mark D. Iannettoni, Mark B. Orringer and Samir Hanash. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nature Medicine. 8(8): 816-24, 2002 (IF:32.621).
  6. Guoan Chen, Tarek G. Gharib, Chiang-Ching Huang, Dafydd G. Thomas, Hong Wang, Kerby A. Shedden, Jeremy M. G. Taylor, Sharon L. R. Kardia, David E. Misek, Thomas J. Giordano, Mark D. Iannettoni, Mark B. Orringer, Samir M. Hanash, and David G. Beer. Overexpression of Oncoprotein 18 Correlates with Poor Differentiation in Lung Adenocarcinomas. Mol Cell Proteomics, 2(2):107-116, 2003 (IF:5.232).
  7. Guoan Chen, Tarek G. Gharib, Dafydd G. Thomas, Chiang-Ching Huang, David E. Misek, Thomas J. Giordano, Mark D. Iannettoni, Mark B. Orringer, Samir M. Hanash and David G. Beer. Proteomic Analysis of eIF-5A in Lung Adenocarcinomas. Proteomics, 3(4): 496-504, 2003 (IF:3.532).
  8. Charles T Miller*, Guoan Chen*, Tarek G Gharib, Hong Wang, Dafydd G Thomas, David E Misek, Thomas J Giordano, John Yee, Mark B Orringer, Samir M Hanash, and David G Beer. Increased C-CRKproto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene, 22(39): 6006-6013, 2003 (* co-first authors) (IF:6.854).
  9. Guoan Chen, Tarek G. Gharib, Hong Wang, Chiang-Ching Huang, Dafydd G. Thomas, Kerby A. Shedden, David E. Misek, Rork D. Kuick, Jeremy M. G. Taylor, Thomas J. Giordano, Sharon L.R. Kardia, Mark D. Iannettoni, John Yee, Philip J. Hogg, Mark B. Orringer, Samir M. Hanash, David G. Beer. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13537-42 (IF:9.661).
  10. Tarek G. Gharib*, Guoan Chen*, Chiang-Ching Huang, David E. Misek, Mark D. Iannettoni, Samir M. Hanash, David G. Beer. Genomic and proteomic analyses of VEGF and IGFBP3 in lung adenocarcinomas. Clinical Lung Cancer 5(5):307-312, 2004, (* co-first authors) (IF:4.204).
  11. Guoan Chen, Hong Wang, Charles T. Miller, Dafydd G. Thomas, Tarek G. Gharib, David E. Misek, Thomas J. Giordano, Mark B. Orringer, Samir M. Hanash, and David G. BeerReduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J. Pathology 202(3):321-9, 2004 (IF:6.253).
  12. José M. Cuezva*, Guoan Chen*, Andrés M. Alonso, Antonio Isidoro, David E. Misek, Samir M. Hanash and David G. Beer.The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis, 25(7):1157-63. Epub 2004 Feb 12, 2004 (* co-first authors) (IF:5.072).
  13. Daly EBChen GSun LFriedlander MGoldstein DBeer DGChesterman CNHogg PJ. Blood level of phosphoglycerate kinase does not correlate with presence or extent of tumor. Int J Biol Markers. 2004 Apr-Jun;19(2):170-2. PMID: 15255553 (IF:1.449).
  14. Shuan-ying Yang, Xue-yuan Xiao, Wang-gang Zhang, Li-juan Zhang, Wei Zhang, Bin Zhou, Guoan Chen, Da-cheng He. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC 5:83, 2005 (IF:3.288).
  15. Guoan ChenMahaveer S. Bhojani, Andrew C. Heaford, Daniel C. Chang, Laura Griffin, James Yu, Dafydd G. Thomas, Thomas J. Giordano, Lin Lin, David Adams,  Mark B. Orringer, Brian D. Ross, David G. Beer, Alnawaz Rehemtulla. Phosphorylated FADD induces NF-kB, cell proliferation, perturbation in cell cycle and is associated with poor outcome in lung adenocarcinomas. Proc Natl Acad Sci U S A. 2005 Aug 30;102(35):12507-12 (IF:9.661).
  16. Mahaveer S. Bhojani*Guoan Chen*, Brian D. Ross, David G. Beer, Alnawaz Rehemtulla. Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer. Cell Cycle. 2005 Nov;4(11):1478-81. (* co-first authors) (IF:3.304).
  17. Mitch Raponi, Yi Zhang, Jack Yu, Guoan Chen, Grace Lee, Jeremy M.G. Taylor, James MacDonald, Dafydd Thomas, Christopher Moskaluk, Yixin Wang and David G. Beer. Gene Expression Signatures for Predicting Prognosis of Squamous Cell and Adenocarcinomas of the Lung. Cancer Res. 66(15):7466-72, 2006 (IF:9.13).
  18. Guoan Chen, Xiaoju Wang, Jianjun Yu, Sooryanarayana Varambally, Jindan Yu, Dafydd G. Thomas, Mu-Yen Lin, Prakash Vishnu, Zhuwen Wang, Rui Wang, Jeff Fielhauer, Debashis Ghosh, Thomas J. Giordano, Donald Giacherio, Andrew C. Chang, Mark B. Orringer, Talal El-Hefnawy, William L. Bigbee, David G. Beer and Arul M. Chinnaiyan. Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. Cancer Res.67(7):3461-7,2007 (IF:9.13).
  19. Jindan Yu, Qi Cao, Rohit Mehra, Bharathi Laxman, Jianjun Yu, Scott A. Tomlins, Chad J. Creighton, Saravana M. Dhanasekaran, Ronglai Shen, Guoan Chen, David S. Morris, Victor E. Marquez, Rajal B. Shah, Debashis Ghosh, Sooryanarayana Varambally and Arul M. Chinnaiyan Integrative Genomics Analysis Reveals Silencing of β-Adrenergic Signaling by Polycomb in Prostate Cancer. Cancer Cell. 12(5):405-7,2007 (IF:22.844).
  20. Jindan Yu, Jianjun Yu, Daniel R. Rhodes, Scott A. Tomlins, Xuhong Cao, Guoan Chen, RohitMehra, Xiaoju Wang, Debashis Ghosh, Rajal B. Shah, Sooryanarayana Varambally, Kenneth J. Pienta and Arul M. Chinnaiyan A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer Outcome. Cancer Res. 67(22):10657-63,2007 (IF:9.13).
  21. Shuanying Yang, Yandong Nan, Yingxuan Tian, Wei Zhang, Bin Zhou, Lina Bu, Shufen Huo, Guoan Chen, Jiekai Yu and Shu Zheng. Study of distinct protein profiles for early diagnosis of NSCLC using LCM and SELDI-TOF-MS. Medical Oncology. 2008 Feb 26. (IF:2.92).
  22. Daniel Albertus*, Christopher W. Seder*, Guoan Chen*, Xiaoju Wang*,Wibisono Hartojo, Lin Lin, Amy Silvers, Daffyd G. Thomas, Thomas J. Giordano, Andrew C. Chang, Mark B. Orringer, William L. Bigbee, Arul M. Chinnaiyan, and David G. Beer. AZGP1 Autoantibody Predicts Survival AND Histone Deacetase Inhibitors Increase Expression in in Lung Adenocarcinoma. J. Thoracic Oncology. 2008 Nov;3(11):1236-44. (* co-first authors) (IF:12.46).
  23. Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG, Giordano TJ, Chen G, Chang AC, Orringer MB, Beer DG. INHBA Overexpression Promotes Cell Proliferation and May Be Epigenetically Regulated in Esophageal Adenocarcinoma. J Thorac Oncol. 2009 Apr;4(4):455-62 (IF:12.460).
  24. Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG, Giordano TJ, Chen G, Chang AC, Orringer MB, Beer DG. Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia. 2009 Apr;11(4):388-96 (IF:4.994).
  25. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, Beer DG. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009 Jul 15;69(14):5776-83. PMID:19584273 (IF:9.13).
  26. Hassan KA*, Chen G*, Kalemkerian GP, Wicha MS, Beer DG. An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res. 2009 Oct 15;15(20):6386-90. PMID:19808871 (* co-first authors) (IF:10.199).
  27. Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, Ponnala R, Cao X, Varambally S, Thomas DG, Giordano TJ, Beer DG, Palanisamy N, Sartor MA, Omenn GS, Chinnaiyan AM. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol. 2009 Nov;27(11):1005-11. PMID: 19881495 (IF:35.724).
  28. Silvers AL, Lin L, Bass AJ, Chen G, Wang Z, Thomas DG, Lin J, Giordano TJ, Orringer MB, Beer DG, Chang AC. Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity. Clin Cancer Res. 2010 Apr 1;16(7):2009-21. PMID: 20332323 (IF:10.199).
  29. Bryant CMAlbertus DLKim SChen GBrambilla CGuedj MArima CTravis WDYatabe YTakahashi TBrambilla EBeer DG.Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study. PLoS One. 2010 Jul 22; 5(7): PMID: 20661423 (IF:2.766).
  30. Yu JCao QYu JWu LDallol ALi JChen GGrasso CCao XLonigro RJVarambally SMehra RPalanisamy NWu JYLatif FChinnaiyan AM. The neuronal repellent SLIT2 is target for repression by EZH2 in prostate cancer. 2010 Sep 30;29(39):5370-80. PMID:20622896 (IF:6.854).
  31. Chen G, Kim SH, King AN, Zhao L, Simpson RU, Christensen PJ, Wang Z, Thomas DG, Giordano TJ, Lin L, Brenner DE, Beer DG, Ramnath N. CYP24A1 Is an Independent Prognostic Marker of Survival in Patients with Lung Adenocarcinoma. Clin Cancer Res. 2010 Dec 17. PMID: 21169243 (IF:10.199).
  32. Meng H*,Chen G*, Zhang X, Wang Z, Thomas DG, Giordano TJ, Beer DG, Wang MM. Stromal LRP1 in Lung Adenocarcinoma Predicts Clinical Outcome. Clin Cancer Res. 2011 Apr 15;17(8):2426-33. PMID: 21325077 (* co-first authors) (IF:10.199).
  33. Ray D, Ahsan A, Helman A, Chen G, Hegde A, Gurjar SR, Zhao L, Kiyokawa H, Beer DG, Lawrence TS, Nyati MK. Regulation of EGFR protein stability by the HECT-type ubiquitin ligase SMURF2. 2011 Jul;13(7):570-8. PMID: 21750651 (IF:4.994).
  34. Gong HC, Wang S, Mayer G, Chen G, Leesman G, Singh S, and Beer DG. Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer. International Journal of Proteomics,2011:215496. PMID:22091388 (IF:).
  35. Chen G, Kim S, Taylor JM, Wang Z, Lee O, Ramnath N, Reddy RM, Lin J, Chang AC, Orringer MB, Beer DG. Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis. J Thorac Oncol. 2011 Sep; 6(9):1481-7. PMID: 21792073 (IF:12.460).
  36. Chen G, Beer DG. Response to translating cancer complexity to clinical decisions. J Thorac Oncol. 2011 Sep;6(9):1456-7. PMID: 21849851(IF:12.460).
  37. Kim SH, Chen G, King AN, Jeon CK, Christensen PJ, Zhao L, Simpson RU, Thomas DG, Giordano TJ, Brenner DE, Hollis B, Beer DG, Ramnath N. Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer. 2012 May 5. PMID: 22564539 (IF:4.486).
  38. Hassan KA, Wang LKorkaya HChen GMaillard IBeer DGKalemkerian GPWicha MS. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res. 2013 Feb 26. PMID:23444212 (IF:10.199).
  39. Li CMChen GDayton TLKim-Kiselak CHoersch SWhittaker CABronson RTBeer DGWinslow MMJacks T. Differential Tks5 isoform expression contributes to metastatic invasion of lung adenocarcinoma. Genes &2013 Jul 15;27(14):1557-67. PMID: 23873940 (IF:9.462).
  40. Grabauskiene S, Bergeron EJ, Chen G, Chang AC, Lin J, Thomas DG, Giordano TJ, Beer DG, Morgan MA, Reddy RM. CHK1 levels correlate with sensitization to pemetrexed by CHK1 inhibitors in non-small cell lung cancer cells. Lung Cancer. 2013 Sep 23.[Epub ahead of print] PMID:24113549 (IF:4.486).
  41. Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, Sanchez-Cespedes M, Assenov Y, Müller F, Bock C, Taron M, Mora J, Muscarella LA, Liloglou T, Davies M, Pollan M, Pajares MJ, Torre W, Montuenga LM, Brambilla E, Field JK, Roz L, Lo Iacono M, Scagliotti GV, Rosell R, Beer DG, Esteller M. A Prognostic DNA Methylation Signature for Stage I Non-Small-Cell Lung Cancer. J Clin Oncol. 2013 Nov 10;31(32):4140-7. PMID: 24081945 (IF:26.303).
  42. Nadal E, Chen G*, Gallegos M, Lin L, Ferrer-Torres D, Truini A, Wang Z, Lin J, Reddy RM, Llatjos R, Escobar I, Moya J, Chang AC, Cardenal F, Capellà G, Beer DG. Epigenetic inactivation of microRNA-34b/c predicts poor disease-free survival in early-stage lung adenocarcinoma.Clin Cancer Res. 2013 Dec 15;19(24):6842-52. PMID: 24130071. (*Co-corresponding author) (IF:10.199).
  43. Grabauskiene S, Bergeron EJ, Chen G, Thomas DG, Giordano TJ, Beer DG, Morgan MA, Reddy RM. Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer. J Surg Res. 2014 Mar; 187(1):6-13. PMID: 24418519 (IF:2.051).
  44. Li H, Tan M, Jia L, Wei D, Zhao Y, Chen G, Xu J, Zhao L, Thomas D, Beer DG, Sun Y. Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis. J Clin Invest. 2014 Feb 3;124(2):835-46. PMID: 24430184 (IF:13.251).
  45. Shukla S, Allam US, Ahsan A, Chen G, Krishnamurthy PM, Marsh K, Rumschlag M, Shankar S, Whitehead C, Schipper M, Basrur V, Southworth DR, Chinnaiyan AM, Rehemtulla A, Beer DG, Lawrence TS, Nyati MK, Ray D. KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradation. 2014 Feb;16(2):115-28. PMID: 24709419 (IF:4.994).
  46. Reka AK*, Chen G*, Jones RC, Amunugama R, Kim S, Karnovsky A, Standiford TJ, Beer DG, Omenn GS, Keshamouni VG. Epithelial-mesenchymal Transition Associated Secretory Phenotype Predicts Survival in Lung Cancer Patients. 2014 Feb; 16 (2):115-28. PMID: 24510113. (* co-first authors) (IF:5.072).
  47. Wan L, Tan M, Yang J, Inuzuka H, Dai X, Wu T, Liu J, Shaik S, Chen G, Deng J, Malumbres M, Letai A, Kirschner MW, Sun Y, Wei W. APC (Cdc20) Suppresses Apoptosis through Targeting Bim for Ubiquitination and Destruction. Dev Cell. 2014 May 27; 29(4):377-91. PMID: 24871945(IF:9.616).
  48. Nadal E, Zhong J, Lin J, Reddy RM, Ramnath N, Orringer MB, Chang AC, Beer DG, Chen G*A MicroRNA Cluster at 14q32 Drives Aggressive Lung Adenocarcinoma. Clin Cancer Res. 2014 Jun 15; 20(12):3107-17. PMID: 24833665 (*Corresponding author) (IF:10.199).
  49. Nadal E, Chen G, Prensner JR, Shiratsuchi H, Sam C, Zhao L, Kalemkerian GP, Brenner D, Lin J, Reddy RM, Chang AC, Capellà G, Cardenal F, Beer DG, Ramnath N. KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma. J Thorac Oncol. 2014 Aug 28. PMID: 25170638(IF:12.460).
  50. Zhang Z, Shiratsuchi H, Lin J, Chen G, Reddy RM, Azizi E, Fouladdel S, Chang AC, Lin L, Jiang H, Waghray M, Luker G, Simeone DM, Wicha MS, Beer DG, Ramnath N, Nagrath S. Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model. Oncotarget. 2014 Dec 15;5(23):12383-97. PMID: 25474037 (IF:5.168).
  51. Dhanasekaran SM*, Alejandro Balbin O*, Chen G*, Nadal E, Kalyana-Sundaram S, Pan J, Veeneman B, Cao X, Malik R, Vats P, Wang R, Huang S, Zhong J, Jing X, Iyer M, Wu YM, Harms PW, Lin J, Reddy R, Brennan C, Palanisamy N, Chang AC, Truini A, Truini M, Robinson DR, Beer DG, Chinnaiyan AM. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat Commun. 2014 Dec 22;5:5893. PMID: (* co-first authors) (IF:12.353).
  52. Balbin OA, Malik R, Dhanasekaran SM, Prensner JR, Cao X, Wu YM, Robinson D, Wang R, Chen G, Beer DG, Nesvizhskii AI, Chinnaiyan AM. The landscape of antisense gene expression in human cancers. Genome Res. 2015 Jul;25(7):1068-79. PMID:26063736 (IF:10.101).
  53. He Y, Wang L, Liu W, Zhong J, Bai S, Wang Z, Thomas DG, Lin J, Reddy RM, Ramnath N, Carrott PW, Lynch WR, Orringer MB, Chang AC, Beer DG, Chen G*MAP3K3 expression in tumor cells and tumor-infiltrating lymphocytes is correlated with favorable patient survival in lung cancer. Sci Rep. 2015 Jun 19;5:11471. PMID: 26088427 (*Corresponding author) (IF:4.122).
  54. Goswami MT*, Chen G*, Chakravarthi BV, Pathi SS, Anand SK, Carskadon SL, Giordano TJ, Chinnaiyan AM, Thomas DG, Palanisamy N, Beer DG, Varambally S. Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. 2015 Sep 15; 6(27):23445-61. PMID: 26140362 (* co-first authors) (IF:5.168).
  55. Nadal E, Truini A, Nakata A, Lin J, Reddy RM, Chang AC, Ramnath N, Gotoh N, Beer DG, Chen G*A Novel Serum 4-microRNA Signature for Lung Cancer Detection. Sci Rep. 2015 Jul 23; 5:12464. PMID: 26202143 (*Corresponding author) (IF:4.122).
  56. Zhao L, Feng D, Chen G, Taylor JM. A unified Bayesian semiparametric approach to assess discrimination ability in survival analysis. Biometrics. 2015 Dec 17. PMID: 26676324 (IF:1.524).
  57. Wang L, He Y, Liu W, Bai S, Xiao L, Zhang J, Dhanasekaran SM, Wang Z, Kalyana-Sundaram S, Balbin OA, Shukla S, Lu Y, Lin J, Reddy RM, Carrott PW Jr, Lynch WR, Chang AC, Chinnaiyan AM, Beer DG, Zhang J, Chen G*Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer. 2016 Feb 5. PMID: 26862852 (*Corresponding author) (IF:5.168).
  58. Raghunathan RCease KTroeschel SZhao LGross MChen GChopra VRamnath N. Impact of Staging with Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans with Stage I-III Non-Small Cell Lung Cancer. Am J Clin Oncol. 2016 Jun 17. PMID:27322696 (IF:3.424).
  59. Shukla S, Evans JR, Malik R, Feng FY, Dhanasekaran SM, Cao X, Chen G, Beer DG, Jiang H, Chinnaiyan AM. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. J Natl Cancer Inst. 2016 Oct 5;109(1). doi: 10.1093/jnci/djw200. Print 2017 Jan.PMID:27707839 (IF:12.589).
  60. Shiratsuchi H, Wang Z, Chen G, Ray P, Lin J, Zhang Z, Zhao L, Beer D, Ray D, Ramnath N. Oncogenic Potential of CYP24A1 in Lung Adenocarcinoma. J Thorac Oncol. 2017 Feb;12(2):269-280. doi: 10.1016/j.jtho.2016.10.010. Epub 2016 Oct 26. PMID:27793774 (IF:12.460).
  61. Xu J, Zhou W, Yang F, Chen G, Li H, Zhao Y, Liu P, Li H, Tan M, Xiong X, Sun Y. The β-TrCP-FBXW2-SKP2 axis regulates lung cancer cell growth with FBXW2 acting as a tumour suppressor. Nat Commun. 2017 Jan 16;8:14002. PMID: 28090088 (IF:12.353).
  62. Zhang J, Feng S, Su W, Bai S, Xiao L, Wang L, Thomas DG, Lin J, Reddy RM, Carrott PW, Lynch WR, Chang AC, Beer DG, Guo YM, Chen G*. Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer. Sci Rep. 2017 Feb 15;7:42819. PMID: 28198463 (*Corresponding author) (IF:4.122).
  63. Liu Y, Bu L, Li W, Wu W, Wang S, Diao X, Zhou J, Chen G, Yang S. Increased AAA-TOB3 correlates with lymph node metastasis and advanced stage of lung adenocarcinoma. Int J Biol Markers. 2017 Jun 15: PMID:28623644 (IF:1.449).
  64. Feng S, Zhang J, Su W, Bai S, Xiao L, Chen X, Lin J, Reddy RM, Chang AC, Beer DG, Chen G*. Overexpression of LINC00152 correlates with poor patient survival and knockdown impairs cell proliferation in lung cancer. Sci Rep. 2017 Jun 7;7(1):2982. PMID: 28592840 (*Corresponding author) (IF:4.122).
  65. Chockley PJ, Chen J, Chen G, Beer DG, Standiford TJ, Keshamouni VG. Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. J Clin Invest. 2018 Jan 11. PMID: 29324443 (IF:13.251).
  66. Su W, Feng S, Chen X, Yang X, Mao R, Guo C, Wang Z, Thomas DG, Lin J, Reddy RM, Orringer MB, Chang AC, Yang Z, Beer DG, Chen G*. Silencing of long non-coding RNA MIR22HG triggers cell survival/death signaling via oncogenes YBX1, MET, and p21 in lung cancer. Cancer Res. 2018 Apr 18. PMID: 29669758 (*Corresponding author) (IF:9.130).
  67. Guo NL, Dowlati A, Raese RA, Dong C, Chen G, Beer DG, Shaffer J, Singh S, Bokhary U, Liu L, Howington J, Hensing T, Qian Y. A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer. EBioMedicine. 2018 May 31. PMID: 29861409 (IF:6.680).
  68. Raghunathan RCease KTroeschel SZhao LGross MChen GChopra VRamnath N Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Managementand Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer. Am J Clin Oncol.2018 May;41(5):513-518, PMID:27322696 (IF:3.424).
  69. Heiden BT, Chen G, Hermann M, Brown RKJ, Orringer MB, Lin J, Chang AC, Carrott PW, Lynch WR, Zhao L, Beer DG, Reddy RM. 18F-FDG PET intensity correlates with a hypoxic gene signature and other oncogenic abnormalities in operable non-small cell lung cancer. PloS One. 2018 Jul 2;13(7): PMID: 29966011 (IF:2.766).
  70. Yu H, Chen Z, Ballman KV, Watson MA, Govindan R, Lanc I, Beer DG, Bueno R, Chirieac LR, Chui MH, Chen G, Franklin WA, Gandara DR, Genova C, Brovsky KA, Joshi MM, Merrick DT, Richards WG, Rivard CJ, Harpole DH, Tsao MS, van Bokhoven A, Shepherd FA, Hirsch FR. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signature for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. J Thorac Oncol. 2019 Jan;14(1):25-36. PMID: 30253973 (IF:12.460).
  71. Su W, Wang L, Niu F, Zou L, Guo C, Wang Z, Yang X, Wu J, Lu Y, Zhang J, Beer DG, Yang Z, Chen G*LINC00857 knockdown inhibits cell proliferation and induces apoptosis via involving STAT3 and MET oncogenic proteins in esophageal adenocarcinoma. Aging (Albany NY). 2019 May 13;11(9):2812-2821. PMID: 31085800 (*Corresponding author) (IF:5.515).
  72. Cheng G, Zhang Q, Pan J, Lee Y, Ouari O, Hardy M, Zielonka M, Myers CR, Zielonka J, Weh K, Chang AC, Chen G, Kresty L, Kalyanaraman B, You M. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019 May 17;10(1):2205. PMID: 31101821 (IF:11.878).
  73. Li L, Kang J, Zhang W, Cai L, Wang S, Liang Y, Jiang Y, Liu X, Zhang Y, Ruan H, Chen G, Wang M, Jia L.Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer. EBioMedicine. 2019 Jun 14. PMID: 31208947(IF:6.680)
  74. Yang X, Zhang Q, Zhang M, Su W, Wang Z, Li Y, Zhang J, Beer DG, Yang S, Chen G*. Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer. Int J Biol Sci. 2019 Jun 10;15(8):1712-1722. doi: 10.7150/ijbs.33986. eCollection 2019. PMID: 31360113 (*Corresponding author) (IF:4.06)
  75. Chen X, Mao R, Su W, Yang X, Geng Q, Guo C, Wang Z, Wang J, Kresty LA, Beer DG, Chang AC, Chen G*Circular RNA circHIPK3 modulates autophagy via MIR124-3p-STAT3-PRKAA/AMPKα signaling in STK11 mutant lung cancer. 2019 Jun 23. doi: 10.1080/15548627.2019.1634945. [Epub ahead of print] PMID: 31232177 (*Corresponding author) (IF:11.059)
  76. Su W, Guo C, Wang L, Wang Z, Yang X, Niu F, Tzou D, Yang X, Huang X, Wu J, Chen X, Zou L, Yang Z, Chen G*LncRNA MIR22HG abrogation inhibits proliferation and induces apoptosis in esophageal adenocarcinoma cells via activation of the STAT3/c-Myc/FAK signaling. Aging (Albany NY). 2019 Jul 10;11. doi: 10.18632/aging.102071. [Epub ahead of print] PMID: 31291201 (*Corresponding author) (IF: 5.515).
  77. Yin Y, Xie CM, Li H, Tan M, Chen G, Schiff R, Xiong X, Sun Y.The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells. Proc Natl Acad Sci U S A. 2019 Sep 23. pii: 201905973. doi: 10.1073/pnas.1905973116. [Epub ahead of print] PMID: 31548378 (IF:9.58)
  78. Xia Yang, Wenmei Su, Xiuyuan Chen, Qianqian Geng, Jingyi Zhai, Hu Shan, Chunfang Guo, Zhuwen Wang, Han Fu, Hui Jiang, Jules Lin, Kiran Hari Lagisetty, Jie Zhang, Yali Li, Shuanying Yang, Pierre P Massion, David G. Beer, Andrew C. Chang, Nithya Ramnath, Guoan Chen*. Validation of A serum 4-microRNA signature for the detection of lung cancer. Translational Lung Cancer Research. 2019 Online (*Corresponding author) (IF: 4.81).
  79. Xia Yang, Qiuhong Zhang, Wenmei Su, Ming Zhang, Hu Shan, Jie Zhang, Guoan Chen, Chunfang Guo, Yali Li. Expression level of serum miRNA-22 and its clinical significance in patients with lung cancer. International Journal of Respiration. 2019 Sep, 39(18), 1373-1378.
  80. Jiang Y, Cheng W, Li L, Zhou L, Liang Y, Zhang W, Chen W, Wang S, Zhao H, Chen G, Zhou W, Ji G, Zhang Y, Hoffman RM, Wang M, Jia L. Effective targeting of the ubiquitin-like modifier NEDD8 for lung adenocarcinoma treatment. Cell Biol Toxicol. 2020 Jan 6. doi: 10.1007/s10565-019-09503-6. [Epub ahead of print] PMID: 31907687 (IF: 5.1).
  81. Lyu X, Zeng L, Zhang H, Ke Y, Liu X, Zhao N, Yuan J, Chen G, Yang S. Hydroxychloroquine suppresses lung tumorigenesis via inducing FoxO3a nuclear translocation through STAT3 inactivation. Life Sci. 2020 Jan 27:117366. doi: 10.1016/j.lfs.2020.117366. [Epub ahead of print], PMID: 32001266 (IF: 3.5).
  82. Huang W, Ray P, Ji W, Wang Z, Nancarrow D, Chen G, Galban S, Lawrence TS, Beer DG, Rehemtulla A, Ramnath N, Ray D. The cytochrome P450 enzyme CYP24A1 increases proliferation of mutant KRAS-dependent lung adenocarcinoma independently of its catalytic activity. J Biol Chem. 2020 Mar 12. pii: jbc.RA119.011869. doi: 10.1074/jbc.RA119.011869. [Epub ahead of print] PMID: 32165494 (IF: 4.13).

1.Methods and compositions for diagnosing lung cancer

Patent number: 7597890

Abstract: The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ubiquilin 1 markers for cancer.

Type: Grant

Filed: March 8, 2007

Date of Patent: October 6, 2009

Assignee: The Regents of the University of Michigan

Inventors: Arul Chinnaiyan, David Beer, Guoan Chen, Xiaoju Wang

2. LUNG CANCER SIGNATURE

Publication number: 20120295803

Abstract: The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to cancer markers as diagnostic markers and clinical targets for lung cancer.

Type: Application

Filed: May 16, 2012

Publication date: November 22, 2012

Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventors: David Beer, Jeremy Taylor, Guoan Chen, Sinae Kim

3.LUNG CANCER SIGNATURE

Publication number: 20150153346

Abstract: The present disclosure relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present disclosure relates to cancer markers as diagnostic markers and clinical targets for lung cancer.

Type: Application

Filed: November 13, 2014

Publication date: June 4, 2015

Inventors: Venkateshwar G. Keshamouni, Gilbert S. Omenn, Guoan Chen, David G. Beer, Theodore J. Standiford

Copyright © 2018 All Rights Reserved.